מחיר רכישת החברה: Kiniksa Corp (KNSA)

Kiniksa Pharmaceuticals (KNSA) specializes in developing orphan biologics, facing a niche market and regulatory barriers. The business model's revenue relies on the sale of innovative treatments for autoimmune and cardiovascular pathologies. A high-demand pericarditis drug, which remains highly relevant, serves as a steady cash generator. The price action confirms these data, fixing the Enterprise Value at 7104.57.

Enterprise Value represents the total capital volume, including market capitalization and net debt, reflecting the actual price for a full buyout of the asset. By analyzing the total business value on GURU.Markets, an investor can see how the exclusive rights to pericarditis drugs and the strong pricing power of Kiniksa Pharmaceuticals (KNSA) justify the company's current valuation relative to its cash flows.